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OBJECTIVES The study sought to determine the effects of lipid-lowering with pravastatin on the systemic
fibrinolytic profile and on thrombus formation under dynamic flow conditions.
BACKGROUND Lowering cholesterol (C) decreases clinical events in coronary artery disease (CAD) patients,
but an analysis of the effects of lipid-lowering on the entire hemostatic and thrombotic profile
has not been conducted.
METHODS We prospectively studied 93 stable patients with untreated low-density lipoprotein cholesterol
(LDL-C) .145 mg/dl. The CAD patients received pravastatin, and non-CAD patients were
randomized to pravastatin versus placebo (double-blind). Thrombus formation upon an
injured vascular surface was assessed in a substudy of 40 patients with a previously validated
ex vivo perfusion chamber system. Systemic hemostatic markers and thrombus formation
were evaluated at baseline, three and six months.
RESULTS Placebo produced no changes in either the lipid profile, any of the hemostatic markers, or the
ex vivo thrombus formation. Both pravastatin groups (CAD and non-CAD) showed
decreased LDL-C by 30% within 6 weeks (188 to 126 mg/dl, p , 0.001 vs. baseline), and
decreased plasminogen activator inhibitor-1 at 3- and 6-month follow-up compared to
baseline (15% to 18% decrease at 3 months and 21% to 23% at 6 months). For the tissue
plasminogen activator antigen, CAD and non-CAD groups showed significant decreases at
6 months compared to baseline (10% and 13%, respectively). No significant changes were
observed with treatment in d-dimer, fibrinopeptide A, prothrombin fragment F1.2, factor
VIIa, von Willebrand factor, or C-reactive protein. Fibrinogen levels were significantly
increased at 6 months compared to baseline, though still below the upper normal limit. In the
perfusion chamber substudy, there was a decrease in thrombus area in non-CAD patients
treated with pravastatin at both 3 and 6 months compared to baseline (by 21% and 34%,
respectively). The CAD patients showed decreases in thrombus formation by 13% at 3
months, and by 16% at 6 months. The change in LDL-C- correlated modestly with the
change in thrombus formation (r 5 0.49; p , 0.01).
CONCLUSIONS Pravastatin therapy significantly decreased thrombus formation and improved the fibrinolytic
profile in patients with and without CAD. These early effects may, in part, explain the benefit
rendered in primary and secondary prevention of CAD. (J Am Coll Cardiol 1999;33:
1294–304) © 1999 by the American College of Cardiology
Hyperlipidemia has been identified as a major risk factor for
the development of coronary artery disease (CAD) (1), and
lipid-lowering has been proven beneficial for the primary
and secondary prevention of CAD (2–4). Reduction of
low-density lipoprotein cholesterol (LDL-C) has been as-
sociated with decreased progression and occasionally with
regression of CAD (5–10), but the most profound effect of
such intervention is the marked decrease in ischemic events
(2–4,11,12).
See page 1305
The development of acute coronary syndromes has
mainly been attributed to thrombus formation upon a
fissured, disrupted, or eroded plaque (13–15). The lipid-
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core is a very strong thrombogenic stimulus when exposed
to the bloodstream (16,17). Elevated cholesterol contributes
to the pathogenesis of endothelial dysfunction, even before
the development of typical atherosclerotic lesions (18).
Occurrence of an acute coronary event may also be due to an
inflammatory and prothrombotic systemic state (19–22).
Previous data suggest that the clinical improvement and
prevention of coronary events with cholesterol lowering may
be achieved by diminishing the plaque lipid content, by
affecting the systemic hemostatic profile or by improving
endothelial function (23–25).
Concerning its effects on thrombosis, treatment of hy-
percholesterolemia with pravastatin has been reported to
decrease platelet aggregation and ex vivo thrombus forma-
tion in CAD patients (26). The effects of several lipid-
lowering agents on certain systemic thrombotic parameters
have also been described in observational studies (27–30).
However, a systemic analysis of the effects of lipid-lowering
on the entire hemostatic and thrombotic profile has not
been conducted in patients with and without CAD.
We prospectively investigated in a randomized, double-
blind, placebo-controlled trial the effects of lowering
LDL-C with pravastatin on thrombus formation, and
parameters that evaluate the entire thrombotic and hemo-
static profile, in a target population without CAD, and a
nonrandomized group with CAD.
METHODS
Patient population and study protocol. Outpatients were
evaluated for possible enrollment at the lipid clinic of the
Mount Sinai Medical Center over a period of 6 months
(December 15, 1995, to June 30, 1996), according to their
fasting lipid profile in the absence of lipid-lowering therapy
for at least 2 months. Patients with LDL-C .145 mg/dl
and triglycerides ,275 mg/dl were considered for enroll-
ment. The presence of CAD was evidenced by a prior
angiogram, or a positive stress test and typical angina, or a
prior myocardial infarction. Patients without CAD had a
negative Rose angina questionnaire (31), as well as no prior
carotid or peripheral atherosclerotic disease. Exclusion cri-
teria were major surgery, major infection, anti-inflammatory
medications, or anticoagulants for the last six months prior
to enrollment. The CAD patients had no history of unstable
angina, myocardial infarction, stroke, angioplasty or bypass
surgery for at least six months prior to enrollment.
Patients with coronary disease were treated with open-
label pravastatin, whereas patients without evidence of
CAD were randomized to pravastatin or placebo. All
patients received an American Heart Association (AHA)
step I diet. No change in cardiac medications was made
during the study period. Diabetics in good glucose control,
as evidenced by fasting blood glucose ,180 mg/dl and
hemoglobin A1c ,8 g%, were included in the study, and the
randomization prospectively stratified their distribution be-
tween the pravastatin and placebo groups in the non-CAD
population. Randomization was done according to a table of
random numbers, kept by the unblinded investigator
(D.A.S.), who was the only one aware of the treatment
assignment and made all decisions regarding the dose of
pravastatin or placebo based on the lipid profile results. The
pre-specified goal was at least a 30% relative reduction of
LDL-C, or an achievement of LDL-C ,125 mg/dl.
Patients were started on 20 mg of pravastatin at bedtime,
and were evaluated at six weeks to assess the efficacy of
LDL-C lowering, and to exclude possible hepatotoxicity. In
case that LDL-C was not 30% lower than baseline or ,125
mg/dl, the pravastatin dose was increased to 40 mg per day.
Placebo patients were evaluated in a similar fashion, took
placebo capsules that were identical to pravastatin, and their
dosage was in equivalent proportion to the pravastatin
patients who required an increased dose.
The Institutional Review Board approved the study, and
all patients granted written informed consent. All patients
had blood drawing (30 ml) for lipid profile, thrombotic and
hemostatic profile (see below) at baseline and after three and
six months of therapy. The patient subset specifically
consenting to participate in the thrombus formation sub-
study had an additional 50 ml of blood withdrawn during
direct ex vivo perfusion through the Badimon chamber (32)
at the same three time points.
Chemical determinations. A complete 12-h fasting lipid
profile was measured at baseline, 6 weeks, 3 and 6 months
after beginning of therapy. Serum transaminases (alanine
aminotransferase [ALT], aspartate aminotransferase [AST])
were also monitored at the same time intervals. The
determinations were performed on a Technicon Chem 1
system (Bayer Diagnostics, Tarrytown, New York) accord-
ing to the manufacturer’s recommendations. Only the un-
blinded investigator had access to these results so as to
ensure patient safety and appropriate therapeutic response
to pravastatin. Serum Lp(a), C-reactive protein (CRP), and
apoproteins A and B were measured with immuno-
turbinometric systems (INCSTAR, Minneapolis, Minneso-
ta), and homocysteine was measured with a fluorescence
detection method. Both Lp(a) and homocysteine levels were
measured only at baseline, as they were unlikely to change
with pravastatin therapy.
Abbreviations and Acronyms
ALT 5 alanine aminotransferase
AST 5 aspartate aminotransferase
CAD 5 coronary artery disease
CRP 5 C-reactive protein
HDL-C 5 high-density lipoprotein cholesterol
LDL-C 5 low-density lipoprotein cholesterol
PAI-1 5 plasminogen activator inhibitor-1
t-PA 5 tissue plasminogen activator
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Thrombotic and hemostatic profile. Several sites of the
coagulation cascade and the hemostatic mechanism were
also evaluated. All blood drawings were performed between
9:00 and 11:30 AM. The patient remained seated for 20 min;
with a tourniquet in place, a 20G cannula was inserted into
an antecubital vein of the patient, and then the tourniquet
was immediately removed. The first 10 ml of blood were
discarded, and then blood was collected for all determina-
tions. Fibrinogen was determined with a heat precipitation
method, prothrombin time/International normalized ratio
was performed on a MLA 900/900C/1000 instrument
(Medical Laboratory Automation, Pleasantville, New York)
and the complete blood count on a Coulter STKS (Coulter,
Hialeah, Florida). Thrombin generation and activity were
assessed by measurement of prothrombin fragment F1.2, and
fibrinopeptide A (FPA) in plasma using commercially
available ELISA kits (Behring Diagnostics, Westwood,
Massachusetts, and Diagnostica Stago, Asnieres-sur-Seine,
France, respectively). Fibrin formation was assessed in
citrated plasma with the d-dimer levels (Diagnostica Stago,
France), and the extrinsic coagulation cascade with factor
VIIa assay as previously described (33). Endothelial markers
were measured with ELISA (American Diagnostica, Green-
wich, Connecticut): plasminogen activator inhibitor-1 (PAI-1)
antigen, tissue plasminogen activator (t-PA) antigen; von
Willebrand factor activity (the latter only in the CAD
group) with a standard assay (Biodata, Philadelphia, Penn-
sylvania). Specimens were centrifuged at 3000g for 20 min,
and then separated and shock-frozen at 275°C. Blood was
unfrozen only once for the determinations, after completion
of the study. Only investigators blinded to the patients’
clinical group conducted these analyses.
Thrombus formation substudy. EX VIVO PERFUSION
CHAMBER. The perfusion chamber system has been de-
scribed elsewhere by Badimon et al. and other investigators
(26,32,34,35). It consists of a cylindrical flow channel,
which allows the blood, pumped directly from the patient to
flow over the exposed thrombogenic substrate. Local flow
conditions, mimicking mild arterial stenosis, were kept
constant: shear rate 1690 s21, Re 5 60, flow rate 10 ml/min,
velocity 21.2 cm/s.
THROMBOGENIC SUBSTRATES. Fresh frozen porcine aorta
was surgically prepared to simulate arterial injury, as previ-
ously described (26,32,34,35). Segments were prepared by
first removing excess adventitia, and after opening the aorta
longitudinally, by peeling off the intima and a thin portion
of the media. Segments were stored at 220°C in 0.1
mol/liter NaCl, 0.01 mol/liter Na3PO4, pH 5 7.4.
PERFUSION STUDIES. During each perfusion study, blood
was circulated through three chambers, connected in series.
The system was connected with polyethylene tubing to the
intravenous line and to a peristaltic pump (Masterflex model
7013, Cole-Palmer Instruments, Denver, Colorado) posi-
tioned distal to the chambers, and flushed with 0.9% NaCl
for 30 s. With a tourniquet in place, a 20G cannula was
inserted into an antecubital vein of the patient, and then the
tourniquet was immediately removed. The first 10 ml of
blood were discarded, and then the ensuing blood was
passed directly from the patient through the chamber
system for 5 min, after which the chambers were flushed
with 0.9% NaCl for 1 min at the same rheologic conditions.
The perfused substrates were then removed from the cham-
bers and placed in formalin at 4°C for 48 to 72 h, and then
processed for immunocytochemistry and light microscopy.
All 50 ml of blood was discarded after perfusion through the
chamber system, and no blood was returned to the patient.
EVALUATION OF THROMBUS FORMATION. As previously
described, serial sections were cut from each formalin-fixed
specimen, and embedded in paraffin. Thin sections were
prepared and stained with 1) combined Mason-elastin stain
and 2) a rabbit polyclonal anti-human fibrinogen antibody
(A080, Dako) at 3.6 mg/ml. For immunohistochemical
staining, the primary antibody was reacted with a biotin-
conjugated secondary antibody, which in turn was reacted
with streptavidin conjugated with peroxidase (BioGenex,
San Ramon, California). Peroxidase activity was detected
with 3-39-diaminobenzidine. Microscopic analyses were
conducted at 100-fold magnification and images were dig-
itized using a Sony DKC-5000 camera and Adobe Photo-
shop 3.0.5 software on a PowerMacintosh 8500 computer.
Thrombus areas were measured on each section with com-
puterized planimetry using NIH Image 1.60 cc software.
The results from the three sections were averaged to
determine the thrombus area for each chamber substrate,
and then the results from the three chambers were averaged
(i.e., a total of nine sections per perfusion study). All
measurements were done by the same investigator (G.D.),
blinded as to the treatment assignment.
Statistical analysis. Patients with CAD formed an indi-
vidual group (open-label pravastatin), whereas non-CAD
patients were randomized into pravastatin and placebo
groups (double-blind treatment and follow-up). The pri-
mary method of comparison, as part of the study design, was
to allow each patient to serve as his or her own control, with
the baseline measurements compared to values at three or
six months’ posttreatment within each group. Analysis of
variance (ANOVA) with Bonferroni correction for multiple
comparisons was used, and significance was defined at the
level p , 0.045. Correlations between continuous variables
were conducted with linear regression analysis. Continuous
variables were expressed as mean 6 SE; categorical variables
were expressed as n(%) and compared with the Fisher exact
test. We also conducted an analysis of covariance between
the placebo group and all pravastatin-treated patients (both
CAD and non-CAD combined) to evaluate differences in
the three-month and six-month follow-up values control-
ling for the respective values obtained at baseline. This was
performed by entering in a multivariate logistic regression
model the observed three- or six-month to baseline changes
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as the outcome, and entering the pravastatin versus placebo
treatment group and the baseline value of the respective
parameter as the two variables. The software JMP 3.2 (SAS
Institute, Cary, North Carolina) was used, and statistical
significance was defined at the level p , 0.05 in other than
ANOVA comparisons.
RESULTS
A total of 226 hyperlipidemic patients without lipid-
lowering therapy for the previous 2 months were evaluated
for possible enrollment in the study. Of those, 88 were
excluded because of their lipid values, 8 for insufficiently
controlled diabetes, 10 for prior angioplasty within 6
months, 5 for prior surgery within 3 months and 3 for
hematocrit ,30%; 9 patients refused to grant consent. The
remaining 103 patients comprised our preliminary study
population: CAD group n 5 32, non-CAD group n 5 71.
Ten did not wish to continue with the study after the first
blood drawing; thus, the final number of participants
incorporated to the analyses was 93: CAD group n 5 31,
non-CAD group n 5 62, divided into pravastatin n 5 26
and placebo n 5 36. Forty of these patients were in the
thrombus formation substudy as well: CAD group n 5 16;
non-CAD group n 5 24, divided into pravastatin n 5 12
and placebo n 5 12.
Baseline patient characteristics are demonstrated in Table
1. The CAD patients were more frequently on aspirin, and
were older, with lower high-density lipoprotein cholesterol
(HDL-C), and were more frequently hypertensive and male
compared to non-CAD patients. Non-CAD pravastatin
versus placebo patients had no differences. There were no
significant baseline differences between the entire popula-
tion and the participants in the thrombus formation sub-
study.
In 64.5% of patients, 20 mg of pravastatin resulted in
appropriate LDL-C reduction within 6 weeks, while the
remaining patients reached the set goal by 3 months, after
an increase in their dose to 40 mg. The response to
pravastatin did not differ among the groups. No patient had
side effects due to pravastatin therapy, or demonstrated an
increase in AST or ALT levels warranting discontinuation
of therapy. The Lp(a) levels were similar in all groups, and
homocysteine levels were slightly higher in the CAD
patients (Table 1).
Changes in lipids, and the thrombotic and hemostatic
profile. Pravastatin therapy decreased both total and
LDL-C at follow-up compared to baseline (Table 2). These
changes were apparent in both patients with and without
CAD. Patients’ weight at follow-up was not significantly
different from baseline for any group. Placebo had no
significant effect on the lipid profile, or in any of the
systemic markers. Hematocrit, CRP and prothrombin time
d-dimer, FPA, F1.2, von Willebrand factor activity, and
factor VIIa did not change significantly with time in any
group. Fibrinogen levels were significantly increased at six
months compared to baseline, in both pravastatin patients
with CAD (11%) and without CAD (21%), but remained
within normal limits, according to laboratory specifications.
In the non-CAD pravastatin-treated group, PAI-1 anti-
gen showed a significant decrease both at three and six
Table 1. Baseline Characteristics in the Entire Study Population (n 5 93)
CAD
Pravastatin
(n 5 31)
No CAD
Pravastatin
(n 5 26)
No CAD
Placebo
(n 5 36)
Age (yrs) 66.5 6 2.0* 64.7 6 2.2 59.6 6 1.9
Gender (Female) (%) 12 (38)* 17 (65) 30 (83)
Smoking (%) 71 (22) 14 (54) 20 (56)
Hypertension (%) 23 (74)* 9 (35) 17 (47)
Diabetes (%) 8 (26) 5 (19) 6 (17)
Family history of CAD (%) 23 (74) 9 (35) 15 (42)
Height (cm) 163.3 6 1.7 159.4 6 4.0 163.8 6 1.4
Baseline weight (kg) 73.8 6 2.7 76.1 6 2.8 82.8 6 3.4
Weight at 6 months (kg) 75.8 6 2.9 77.5 6 3.2 83.0 6 4.0
Systolic BP (mm Hg) 147.2 6 3.8 143.1 6 4.6 138.0 6 3.4
Systolic BP at 6 months (mm Hg) 141.3 6 3.3 133.1 6 4.3 137.1 6 3.5
Diastolic BP (mm Hg) 78.4 6 1.8 79.4 6 2.3 76.8 6 2.1
Diastolic BP at 6 months (mm Hg) 73.9 6 2.2 75.5 6 2.2 74.8 6 2.2
Ca channel-blocker use (%) 10 (32) 7 (27) 11 (31)
ACE-inhibitor use (%) 15 (48) 5 (19) 8 (22)
b-blocker use (%) 9 (29) 2 (8) 2 (6)
Aspirin use (%) 25 (81)* 9 (35) 11 (31)
Lipoprotein(a) (mg/dl) 51.6 6 6.1 46.1 6 7.2 51.1 6 6.6
Homocysteine (mmol/liter) 20.3 6 1.4 17.4 6 1.0 15.1 6 0.6
*p , 0.05 vs. non-CAD patients.
ACE 5 angiotensin-converting enzyme; BP 5 arterial blood pressure; CAD 5 coronary artery disease.
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Table 2. Hemostatic Factors in the Entire Study Population (n 5 93)
CAD No CAD No CAD
Pravastatin Pravastatin Placebo
Total cholesterol (mg/dl) Baseline 264.8 6 5.1 277.0 6 7.6 265.5 6 4.3
3 months 206.4 6 5.6* 205.5 6 6.8* 260.3 6 6.0
6 months 205.7 6 6.3* 212.5 6 6.0* 265.0 6 8.1
Change 0–3 58.3 6 4.7‡ 71.5 6 6.6‡ 5.1 6 6.2
Change 0–6 60.5 6 6.1‡ 63.0 6 6.6‡ 1.5 6 7.0
LDL cholesterol (mg/dl) Baseline 191.5 6 5.1 192.8 6 7.0 185.1 6 4.0
3 months 134.7 6 5.6* 125.1 6 5.4* 180.7 6 5.1
6 months 136.5 6 6.6* 131.5 6 5.7* 188.8 6 6.9
Change 0–3 56.8 6 4.5‡ 67.6 6 6.1‡ 4.3 6 4.9
Change 0–6 56.5 6 5.8‡ 57.9 6 6.5‡ 24.1 6 6.2
HDL cholesterol (mg/dl) Baseline 41.6 6 1.6 54.2 6 3.4 51.1 6 2.3
3 months 41.4 6 1.6 55.0 6 3.4 48.5 6 2.0
6 months 39.1 6 2.0† 56.1 6 3.6 50.7 6 2.5
Change 0–3 0.1 6 1.2† 20.7 6 1.1 2.5 6 1.2
Change 0–6 2.4 6 1.5† 0.5 6 1.7 1.5 6 1.1
Apoprotein A (mg/dl) Baseline 131.5 6 3.4† 161.6 6 7.3 149.2 6 4.2
3 months 138.7 6 3.9† 163.8 6 6.7 149.7 6 3.6
6 months 134.7 6 3.9† 162.9 6 7.0 152.4 6 5.1
Change 0–3 27.1 6 2.3 22.1 6 2.9 21.2 6 3.5
Change 0–6 25.1 6 2.6 2.0 6 4.3 21.2 6 2.4
Apoprotein B (mg/dl) Baseline 141.3 6 3.5 135.0 6 4.6 133.0 6 3.6
3 months 111.1 6 3.9* 100.2 6 4.0* 134.2 6 4.0
6 months 111.9 6 4.4* 101.5 6 4.2* 134.6 6 4.3
Change 0–3 30.1 6 2.7‡ 34.8 6 3.4‡ 22.0 6 3.2
Change 0–6 30.8 6 3.5‡ 33.8 6 3.8‡ 22.8 6 3.2
Fibrinogen (mg/dl) Baseline 332.0 6 14.2 303.2 6 21.9 338.5 6 13.6
3 months 347.0 6 16.0* 347.8 6 21.3* 321.6 6 12.9
6 months 365.4 6 12.9* 354.8 6 20.7* 318.2 6 15.5
Change 0–3 28.5 6 12.3‡ 250.3 6 25.6 12.1 6 13.3
Change 0–6 237.3 6 16.9‡ 265.2 6 23.4‡ 25.6 6 16.1
t-PA (ng/ml) Baseline 12.0 6 0.8 12.1 6 0.9 9.2 6 0.5
3 months 13.0 6 0.9 12.0 6 1.0 9.4 6 0.6
6 months 10.6 6 0.9** 11.2 6 1.0* 9.4 6 0.6
Change 0–3 21.2 6 0.4 0.06 6 0.6 20.3 6 0.3
Change 0–6 1.2 6 0.4‡ 1.6 6 0.2‡ 20.5 6 0.4
PAI-1 (ng/ml) Baseline 38.9 6 2.2 43.2 6 4.0 32.5 6 2.8
3 months 33.2 6 2.7** 35.5 6 2.5* 36.8 6 2.8
6 months 30.9 6 2.9* 33.2 6 2.9* 32.6 6 2.4
Change 0–3 6.0 6 2.7‡ 7.7 6 2.7‡ 23.3 6 2.3
Change 0–6 8.3 6 2.3‡ 10.0 6 2.2‡ 20.2 6 3.3
Factor VIIa (ng/ml) Baseline 2.5 6 0.2 2.8 6 0.3 2.3 6 0.2
3 months 2.2 6 0.2 2.5 6 0.2 2.4 6 0.2
6 months 2.4 6 0.3 2.6 6 0.2 2.5 6 0.3
Change 0–3 0.3 6 0.1 0.3 6 0.1 20.08 6 0.1
Change 0–6 0.05 6 0.1 0.2 6 0.2 20.09 6 0.1
CRP (mg/l) Baseline 3.4 6 0.8 3.6 6 1.2 6.2 6 1.4
3 months 5.4 6 1.5 4.2 6 1.1 5.8 6 1.2
6 months 3.5 6 1.1 5.7 6 1.5 6.4 6 1.4
Change 0–3 21.9 6 0.9 20.6 6 0.8 0.2 6 0.6
Change 0–6 20.2 6 0.6 22.3 6 1.4 0.5 6 0.9
*Significant difference compared to baseline (**indicates analysis of covariance); ‡significant difference compared to placebo; †significant difference compared to non-CAD
patients.
Observed differences were also significant after adjustment for differences in platelet count.
(continued on next page)
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months of follow-up compared to baseline (by 18% and
23%, respectively, p , 0.04). Similarly, a significant de-
crease at 6 months compared to baseline occurred in t-PA
levels of the same group (by 13%, p , 0.04). In the CAD
patients treated with open-label pravastatin, PAI-1 was
significantly reduced at 3 months compared to baseline (by
15%, p , 0.04), and both t-PA and PAI-1 were signifi-
cantly decreased compared to baseline at the 6-month
follow-up (by 10% and 21%, respectively, p , 0.04).
Effect on thrombus formation. At baseline, non-CAD
patients randomized to pravastatin had somewhat larger
thrombus cross-sectional area as compared to CAD patients
or to placebo patients. In response to pravastatin therapy,
there was a significant decrease in thrombus area in non-
CAD patients at both three and six months compared to
baseline (21% and 34%, respectively, p , 0.04). Compared
to baseline, CAD patients showed a trend to decreased
thrombus formation at three months (by 13%, p , 0.09),
and a significant decrease at six months of therapy (by 16%,
p , 0.04). Placebo produced no significant changes in
thrombus formation at either time point (Fig. 1). Changes
in thrombus formation that occurred in either pravastatin
group were significantly different compared to changes in
the placebo group.
We found no significant correlation between LDL-C
(also total cholesterol) and total thrombus area in all
patients studied at baseline. However, a direct linear corre-
lation existed between change in LDL-C and change in
thrombus formation (Fig. 2), with an r value of 0.47 for the
three-month-to-baseline change, and an r value of 0.48 for
the six-month-to-baseline change (p , 0.01). Reduction in
LDL-C accounted for 23% in the reduction observed in
thrombus formation under dynamic flow conditions.
Patients included in the perfusion chamber substudy
demonstrated similar trends in their hemostatic profile as
the entire study population. The non-CAD as well the
CAD pravastatin-treated patients had significant decreases
(vs. baseline) in PAI-1 and t-PA after 6 months of therapy,
whereas no significant changes were observed with placebo:
CAD patients’ PAI-1 from 40.2 6 4.4 to 31.3 6 2.9 ng/ml,
and t-PA from 11.7 6 1.1 to 9.7 6 1.0 ng/ml; non-CAD
patients’ PAI-1 from 42.8 6 6.3 to 30.0 6 5.4 ng/ml, and
t-PA from 9.5 6 0.9 to 8.6 6 0.9 ng/ml, p , 0.045 for all.
Analysis of covariance. This analysis provided the adjusted
mean values of patients treated with placebo (n 5 36) versus
pravastatin (n 5 57), controlling for the baseline between-
group differences in the examined values; for the perfusion
chamber substudy, the corresponding numbers were n 5 28
for pravastatin, n 5 12 for placebo (Table 3). At the
three-month follow-up visit, PAI-1 was significantly lower
and thrombus formation was borderline lower in
pravastatin-treated patients compared to placebo. At the
Table 2. Continued
CAD No CAD No CAD
Pravastatin Pravastatin Placebo
FPA (ng/ml) Baseline 4.7 6 0.7 3.7 6 0.8 4.2 6 0.6
3 months 3.9 6 0.7 4.3 6 0.7 5.3 6 1.2
6 months 3.3 6 0.5 5.6 6 1.4 5.3 6 1.2
Change 0–3 0.4 6 0.8 20.7 6 1.4 21.1 6 1.4
Change 0–6 2.0 6 1.0 22.6 6 1.8 21.6 6 1.3
F1.2 (nmol/l) Baseline 1.7 6 0.1 2.5 6 0.4 1.8 6 0.2
3 months 1.6 6 0.2 2.1 6 0.3 2.4 6 0.5
6 months 1.3 6 0.1 1.7 6 0.2 2.0 6 0.5
Change 0–3 20.06 6 0.2 0.4 6 0.3 20.7 6 0.5
Change 0–6 0.3 6 0.2 0.54 6 0.4 20.3 6 0.6
d-dimer (ng/ml) Baseline 473.6 6 73.8 384.3 6 46.3 365.2 6 32.6
3 months 386.6 6 45.5 445.0 6 75.0 371.8 6 50.6
6 months 36.0 6 52.4 338.2 6 46.9 329.1 6 32.3
Change 0–3 86.9 6 48.4 260.7 6 46.7 23.4 6 35.6
Change 0–6 99.1 6 58.9 46.0 6 59.5 30.0 6 21.7
von Willebrand factor activity (%) Baseline 83.4 6 8.1
3 months 82.0 6 8.4
6 months 79.8 6 6.0
Change 0–3 1.4 6 8.6
Change 0–6 20.1 6 4.0
Platelet count (103/ml) Baseline 230.4 6 9.6 240.3 6 10.4 237.1 6 8.9
3 months 208.2 6 9.3* 241.2 6 10 233.3 6 8.6
6 months 232 6 11.4 240.6 6 12.5 230.0 6 10.4
Change 0–3 21.6 6 5.0‡ 1.6 6 5.4 4.2 6 4.6
Change 0–6 5.3 6 7.8 0.6 6 8.6 7.6 6 7.2
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six-month follow-up, values of thrombus formation and
t-PA were significantly lower, and PAI-1 was borderline
lower in pravastatin-treated patients compared to placebo.
Effect of aspirin on the response to pravastatin. In a
secondary analysis, we investigated the possible correlation
of the use of aspirin to the changes in thrombus formation
that occurred in the entire pravastatin-treated patient pop-
ulation (n 5 57). Decreases in thrombus formation tended
to be somewhat greater and occurred earlier in the non-
CAD patients. Thrombus formation in the perfusion cham-
ber was greater at baseline in patients not receiving aspirin
(Fig. 3), and six-month-to-baseline decreases in thrombus
area with pravastatin were significantly greater in patients
not treated with aspirin versus those treated with aspirin:
5.3 6 1.0 vs. 1.7 6 0.9 mm2 3 103, respectively, p , 0.04
(Fig. 4).
DISCUSSION
Several studies have assessed the effects of cholesterol-
lowering agents on platelet function, endogenous fibrinoly-
sis and fibrinogen, showing decreased platelet reactivity and
aggregability with cholesterol-lowering therapy (30). La-
coste et al. (26) reported a reduction of the increased
thrombogenic potential of hypercholesterolemic CAD pa-
tients after 3 months of pravastatin therapy. The present
Figure 1. Changes of total thrombus area in the three study groups (perfusion chamber substudy). Significant changes (p , 0.04)
compared to baseline are indicated by asterisk (*).
Figure 2. Perfusion chamber substudy (n 5 40): correlation
between change in LDL-cholesterol and total thrombus area after
6 months of therapy.
Table 3. Analysis of Covariance: Values Adjusted for Baseline
Differences
Pravastatin
(n 5 57)
Placebo
(n 5 36) p
t-PA at 3 months
(ng/ml)
11.7 6 0.3 11.4 6 0.5 NS
t-PA at 6 months
(ng/ml)
9.8 6 0.3 11.5 6 0.4 0.003
PAI-1 at 3 months
(ng/ml)
32.7 6 1.5 38.3 6 2.0 0.03
PAI-1 at 6 months
(ng/ml)
30.6 6 1.5 35.0 6 2.0 0.08
Thrombus area
(mm2 3 103)
n 5 28 n 5 12
Thrombus area
3 months
11.1 6 0.5 12.9 6 0.8 0.08
Thrombus area
6 months
10.3 6 0.7 13.4 6 1.2 0.04
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study reports for the first time a direct correlation between
reduction in LDL-C and reduction in thrombus formation
(Fig. 2). The reduction in LDL-C explained only 23% of
that change in thrombus formation (r2 5 0.23). This
suggests that the decrease in thrombus formation and the
improvement in the systemic fibrinolytic profile may not be
exclusively related to lipid reduction.
The effects of lipid-lowering on fibrinogen have been
variable, with studies showing a decrease, no change, or an
increase with statin therapy (28,36,37). In the present study,
there was an increase in fibrinogen that was, however, not
associated with changes in markers of thrombin generation
and activity and fibrinogen levels remained below the upper
limit of normal. Lipid-lowering may render the plaques
less prone to rupture, or render them less thrombogenic
when exposed to flowing blood after rupture (38). Treat-
ment of hypercholesterolemia has been shown to improve
endothelium-dependent coronary vasomotion (24,25,39),
implying a beneficial effect at the early stages of atherogen-
esis.
Elevated t-PA levels have been demonstrated in condi-
tions related to endothelial cell damage (40), and may also
occur in relation to intravascular thrombus formation (41).
Several studies, most showing a decrease, have evaluated the
effects of lipid-lowering on endogenous fibrinolysis by
measuring systemic levels of t-PA and PAI-1. As these
substances are produced by endothelial cells, the decrease in
their plasma levels reflects improved intrinsic fibrinolysis,
and is also likely to represent an improvement in endothelial
function and a “decreased thrombotic potential.” In fact,
most of the t-PA in the plasma circulates bound to PAI-1
molecules (42); therefore, higher t-PA and PAI-1 levels
likely reflect an attenuated fibrinolytic state, and a decrease
in both parameters represents an enhancement of intrinsic
fibrinolysis (43) related to improved endothelial function
with pravastatin therapy.
We systematically evaluated the thrombotic and hemo-
static profile of hyperlipidemic patients with and without
evidence of CAD. Our results support an inhibitory effect of
pravastatin therapy on platelet thrombus formation, and the
systemic hemostatic profile. Thrombin generation, throm-
bin activity and the intrinsic coagulation cascade were not
affected by treatment in this study. The levels of CRP were
uniformly low in all patient groups at baseline and remained
so throughout the study duration. It is possible that induced
changes in these parameters may be too small to detect with
the present sample size and the given parameter variability
(20). Nonetheless, the importance of platelet and fibrino-
lytic/endothelial function in arterial thrombosis has recently
received greater attention than the coagulation cascade
(19,44). In that respect, small changes in coagulation
parameters may not have as great an implication concerning
the occurrence of coronary events compared to changes in
platelet reactivity and an improved hemostatic profile re-
lated to endothelial function (45–51).
These effects on thrombus formation were apparent in
both CAD and non-CAD patients treated with pravastatin,
and the effects of therapy were more accentuated in the
non-CAD group. This might have been related to the
greater number of risk factors for vascular disease in the
CAD group (i.e., lower HDL-C, higher age, more male,
and more hypertension). Additionally, CAD versus non-
CAD patients had a significantly greater use of aspirin.
Because pravastatin therapy appeared to improve the plate-
let/endothelium relationship and to diminish the formation
of platelet thrombus, preexisting aspirin therapy might have
limited the window of expected benefit from pravastatin,
which was fully demonstrated in our hyperlipidemic patients
with CAD.
Our results offer insights into possible mechanisms for
the reduction in clinical events with pravastatin therapy in
the prevention of CAD. Thrombus formation upon an
Figure 3. Perfusion chamber substudy (n 5 40): baseline total thrombus formation was significantly lower (*p , 0.04) in patients receiving
aspirin compared to those who were not treated with aspirin.
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injured vascular surface and the endothelial hemostatic
markers changed favorably with pravastatin. Along with the
reduction in LDL-C and the potential for plaque stabiliza-
tion, pravastatin appears to affect significantly platelet reac-
tivity, platelet–vessel wall interaction, endothelial function
and intrinsic fibrinolysis. Recently, treatment with pravasta-
tin in the West of Scotland primary prevention study was
reported to be equivalent in reducing coronary events at all
levels of LDL reduction greater than 23%, implying that the
magnitude of LDL-lowering was not the sole determinant
for the observed clinical benefit in the treatment arm (52). A
similar effect was also evident in the CARE trial (53), which
demonstrated no additional benefit from LDL-lowering
below a treatment level of 125 mg/dl, and no relationship
between LDL reduction and cardiac events.
The present investigation does not provide comparative
information regarding different statins and their individual
effect on platelet–vessel wall interaction and the thrombotic
and hemostatic profile. Preliminary reports have indicated
that these properties may differ among the statins, as
simvastatin failed to show such effects on platelet thrombus
formation in one pilot study, while it decreased thrombus
formation in another (54,55). The interrelation between
aspirin and pravastatin therapies on thrombus formation
should be further investigated, as should differences among
statins in thrombus formation and the systemic hemostatic
profile.
Conclusions. Treatment of hyperlipidemic patients with
pravastatin correlated with a reduction in thrombus forma-
tion upon an injured vascular surface under dynamic flow
conditions, and with an improvement in fibrinolytic mark-
ers. The modest correlation between the change in LDL-C
and the changes in these markers suggests that the observed
changes in the thrombotic markers were only in part due to
the reduction of LDL-C.
Reprint requests and correspondence: Dr. John A. Ambrose,
Chief of Cardiology (Cronin 553), Saint Vincent’s Hospital and
Medical Center, 153 West 11th Street, New York, New York
10011.
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